Tianjin Jianfeng has another postdoctoral student out of the station.
Release time:
2023-07-11
Dr. Li Dongnan has presided over and participated in 18 national, provincial and municipal scientific research projects such as the National Key Research and Development Program, the National Natural Science Foundation of China, and major projects in Liaoning Province. He has published more than 20 papers in high-level journals at home and abroad, including 6 SCI Zone 1 (JCR) papers and 2 EI papers as the first author and corresponding author. Won the first prize and second prize of the provincial and ministerial science and technology progress award twice. After entering Tianjin Jianfeng postdoctoral workstation, Li Dongnan, taking "the mechanism of pectin improving the stability of anthocyanins in fruit juice" as the research topic, deeply studied and excavated plant resources rich in anthocyanins or other functional components, and expanded the application of non-thermal processing technologies such as HHP in food processing.
This defense meeting was jointly held by Tianjin Jianfeng and Tianjin University of Science and Technology. The review experts included Liu Dan, general manager of Tianjin Jianfeng, Du Xinjun, dean of the School of Food Science and Engineering of Tianjin University of Science and Technology, and professors Zhang Zesheng, Hu Aijun, Wang Hao, etc. After defense, the expert group believed that Dr. Li Dongnan's research took cyanidin -3-glucoside (C3G) and blueberry pectin (BP) as objects, and used high hydrostatic pressure treatment to explore their influence on the physical and chemical properties and microscopic morphology of C3G-BP complexes and their protective effect on anthocyanin stability, and to study the biological activity of C3G-BP complexes. The relevant research results have great theoretical significance and application value. At the same time, during his stay at the station, Li Dongnan successively published 2 papers in SCI I Area I of the Chinese Academy of Sciences, 1 paper in Area II and 1 paper included in EI, assisted enterprises in applying for 1 invention patent, and newly presided over 1 general project of Liaoning Provincial Nature Fund and 1 general project of Liaoning Provincial Education Department. Relevant research results meet the requirements of outbound conditions. Liu Dan, general manager of Tianjin peak
, said that with people's attention to their own health, the demand for plant health food and functional food characterized by "homology of food and medicine" is increasing. Only by continuously improving product quality and optimizing product functions can the medical and health industry have a better development. Tianjin Jianfeng postdoctoral workstation is a national postdoctoral workstation. Tianjin Jianfeng has always regarded the training of postdoctoral students as an important work. It has invested a lot of energy in the construction of the workstation, the selection of candidates and research topics, and the training of talents in the station. It not only improves the gold content of research results, but also actively explores the follow-up transformation of results.
It is also understood that Li Dongnan is the fifth postdoctoral in Tianjin Jianfeng postdoctoral workstation. At present, there are two more doctors with cooperation intention waiting for further examination and entry. (Xu Rui)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page